The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Should all patients (pts) with advanced biliary cancers receive first-line treatment with cisplatin and gemcitabine (GC)?
Vanessa Costa Miranda
No relevant relationships to disclose
Luiza Dib-Faria
No relevant relationships to disclose
Maria Ignez Freitas Melro Braghiroli
No relevant relationships to disclose
Jorge Sabbaga
No relevant relationships to disclose
Daniel Fernandes Saragiotto
No relevant relationships to disclose
Gilberto Castro
No relevant relationships to disclose
Paulo M. Hoff
No relevant relationships to disclose
Rachel Riechelmann
No relevant relationships to disclose